News | April 09, 2009

Stem Cell Treatment for Myocardial Disease Trial Largest of its Kind in U.S.

April 9, 2009 - A successful randomized, double-blinded, placebo-controlled phase 2 clinical trial using an intramyocardial injection of a patient’s own CD34 stem cells as treatment for refractory angina has been completed, and included 22 centers across the U.S.

The phase 2 study, designed to test the ability of a patient’s own stem cells (CD34 cells) to improve blood flow to the heart, could show the ability to improve heart function and reduce the possibility of events such as hospitalizations and heart failure in patients with refractory angina. A total of 167 patients were randomized and completed the injection procedure, and 162 patients completed the six-month evaluation.

“The results from this study provide the first significant evidence that a patient’s own stem cells can actually be used as a treatment for their heart disease,” said Douglas Losordo, M.D., lead author from Northwestern University, Chicago. “This study provides some hope for those patients with currently untreatable angina to be more active with less pain.”

Dr. Losordo presented the study “Randomized, Double-blind Placebo Controlled Phase 2 Study of Intramyocardial Injection of Autologous CD34+ Cells for Treatment of Refractory Angina during the recent ACC conference in Orlando, FL.

Phase 2 of the study provides information about appropriate endpoints regarding suitability and sample size of this therapy for a phase 3 efficacy study, the final study that will ultimately determine if the treatment works.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init